Kailera Therapeutics, Inc. (KLRA)
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Kailera Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 129.64M shares outstanding
USKailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations.
The company was founded in 2024 and is based in Waltham, Massachusetts.
Leadership
Jamie Beth Coleman
Chief Commercial Officer
Ronald C. Renaud Jr.
President, CEO & Director
Paul Douglas Burgess
Chief Operating & Business Officer
Corey Manchester
Treasurer
Employees
145
Country
US
Sector
Healthcare
Website
www.kailera.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Nicholson Nur | Chief Technology Officer | Grant/Award | 220.0K | -- | Sep 7, 2026 |
 Tregoning Kathleen | See Remarks | Grant/Award | 175.0K | -- | Jul 6, 2026 |
 Renaud Ronald C JR | CEO & President | Option Exercise | 38.1K | $200.0K | Jun 9, 2026 |
| Renaud Ronald C JR | CEO & President | Option Exercise | 38.1K | -- | Jun 9, 2026 |
 Koppel Adam | Director | Purchase | 1.56M | $25.00M | Apr 20, 2026 |
 Bain Capital Life Sciences Investors, LLC | 10% Owner | Conversion of Derivative | 16.88M | -- | Apr 20, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BAIN CAPITAL INVESTORS LLC | 26.3M | 20.3% | 13F |
BCPE Perseus Investor, LP · may incl. warrants· filed Apr 2026 | 26.3M | 20.3% | 13D |
Bain Capital Life Sciences Investors, LLC | 22.6M | 17.4% | 13F |
BCLS Fund IV Investments, L.P. · may incl. warrants· filed Apr 2026 | 22.6M | 17.4% | 13D |
RTW INVESTMENTS, LP | 10.8M | 8.3% | 13F |
CANADA PENSION PLAN INVESTMENT BOARD | 7.3M | 5.6% | 13F |
Atlas Venture Life Science Advisors, LLC | 5.2M | 4.0% | 13F |
FMR LLC | 4.0M | 3.1% | 13F |
BlackRock, Inc. | 3.9M | 3.0% | 13F |
PRICE T ROWE ASSOCIATES INC /MD/ | 3.5M | 2.7% | 13F |
Insiders
- Nicholson NurChief Technology Officer
- Tregoning KathleenSee Remarks
- Renaud Ronald C JRCEO & President
- Koppel AdamDirector
- Bain Capital Life Sciences Investors, LLC10% Owner
- Kaplan Andrew T.Director
- RTW INVESTMENTS, LP10% Owner
- BAIN CAPITAL INVESTORS LLC10% Owner
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% Owner
- Burgess Paul D.See Remarks
based on 129.64M shares outstanding
US30d Avg
1.37M
60d Avg
1.25M
90d Avg
1.01M